Results 181 to 190 of about 7,531 (200)
Some of the next articles are maybe not open access.
Mf59 ® -Adjuvanted Seasonalinfluenza Vaccine
Aging Health, 2009Correlated with increasing chronologic age, immunosenescence impairs the response to influenza vaccines. MF59®-adjuvanted influenza vaccine (Fluad®, Novartis, Basel, Switzerland) elicits a stronger and broader immune response against well-matched and drifted influenza strains compared with conventional vaccines. MF5-adjuvanted influenza vaccine reduces
openaire +1 more source
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
Vaccine, 1999Safety and immunogenicity of the influenza vaccine adjuvanted with MF59 (FLUAD) were compared to those of a non adjuvanted subunit vaccine in elderly subjects during three consecutive influenza seasons. Geometric mean titres and proportions of subjects with either a > or = four-fold increase in antibody titres or with an HI titre > or = 128 after ...
S, De Donato +9 more
openaire +2 more sources
Exposure to MF59-adjuvanted influenza vaccines during pregnancy—A retrospective analysis
Vaccine, 2010Pregnant women are at increased risk for complications and death associated with pandemic H1N1 influenza infection and they are prioritized for vaccination by public health authorities. Few data are available on the safety of adjuvants as components of pandemic vaccines that could be given systematically to pregnant women.
Theodore, Tsai +5 more
openaire +2 more sources
The mechanism of action of MF59 – An innately attractive adjuvant formulation
Vaccine, 2012MF59 is a safe and effective vaccine adjuvant which was originally approved to be included in a licensed influenza vaccine to be used in the elderly in Europe in 1997. The MF59 adjuvanted influenza vaccine (Fluad™) is now licensed in more than 20 countries worldwide and more than 85 million doses have been administered.
D T, O'Hagan +3 more
openaire +2 more sources
Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice
Vaccine, 1999MF59, which is an adjuvant approved for human use, typically elicits higher antibody titers than alum when used in combination with a variety of recombinant and natural subunit antigens. The mechanisms responsible for the adjuvant action of MF59 are not fully understood.
M, Dupuis, D M, McDonald, G, Ott
openaire +2 more sources
ChemInform Abstract: MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines
ChemInform, 2012AbstractReview: 58 refs.
openaire +1 more source
Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant
Pediatric Infectious Disease Journal, 2009Children have high morbidity and hospitalization rates from seasonal influenza. Meta-analyses suggest that conventional inactivated influenza vaccines are of low efficacy in young children, making vaccines that induce greater and broader immune protection in this vulnerable population a medical priority.
Timo, Vesikari +6 more
openaire +2 more sources
MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)
Pharmaceutical Research, 2009The effectiveness of vaccines depends on the age and immunocompetence of the vaccinee. Conventional non-adjuvanted influenza vaccines are suboptimal in the elderly and vaccines with improved ability to prevent influenza are required. The TLR4 agonist E6020, either given alone or co-delivered with MF59, was evaluated and compared to MF59 and the TLR9 ...
Barbara C, Baudner +8 more
openaire +2 more sources
Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly
Vaccine, 2007In a randomized, observer-blind, three-arm, parallel group, multi-centre trial including 386 elderly subjects in four countries, the immunogenicity and safety was studied of three different trivalent inactivated surface antigen (subunit) influenza vaccine types: a conventional subunit influenza vaccine (SIV, brand: Influvac and two newer vaccines: a ...
Iris, de Bruijn +5 more
openaire +2 more sources